ABSTRACT: Confirmatory detection of diseases, such as HIV and HIVassociated pathogens in a rapid point-of-care (POC) diagnostic remains a goal for disease control, prevention, and therapy. If a sample could be analyzed onsite with a verified result, the individual could be counseled immediately and appropriate therapy initiated. Our group is focused on developing a microfluidic "lab-on-a-chip" that will simultaneously identify antigens, antibodies, RNA, and DNA using a single oral sample. The approach has been to design individual modules for each assay that uses similar components (e.g., valves, heaters, metering chambers, mixers) installed on a polycarbonate base with a common reporter system. Assay miniaturization reduces the overall analysis time, increases accuracy by simultaneously identifying multiple targets, and enhances detector sensitivity by upconverting phosphor technology (UPT). Our microfluidic approach employs four interrelated components: (1) sample acquisitionOraSure UPlink TM collectors that pick-up and release bacteria, soluble analytes, and viruses from an oral sample; (2) microfluidic processingmovement of microliter volumes of analyte, target analyte extraction and amplification; (3) detection of analytes using UPT particles in a lateral flow system; and (4) software for processing the results. Ultimately, the oral-based microscale diagnostic system will detect viruses and bacteria, associated pathogen antigens and nucleic acids, and antibodies to these pathogens.
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BACKGROUND

Scope of the HIV Diagnostic Problem
HIV is a major pathogen challenging the global community and it is well recognized that HIV/AIDS is a leading cause of illness and death in the United States. In 2006, more than 1 million people living in the United States have been diagnosed with HIV/AIDS and more than 500,000 individuals have died over the last 25 years. 1 It was estimated that globally in 2005, 34 to 46 million people were infected with HIV, approximately 4.1 million new infections occurred, and 3 million deaths resulted. Dr. Kevin M. De Cock, Director of the WHO AIDS program, reported at the 16th International AIDS Conference that approximately 2.3 million children up to the age of 15 years around the world are infected with HIV. 2 Of the 38.6 million people worldwide with HIV, about 6.8 million are in low-and middle-income communities and can be expected to die within 2 years without antiretroviral therapy. Only about 4% of this infected population are now receiving therapy. 2 The rate of HIV infection in the USA is estimated to be 0.6% annually compared to a level of ∼19% in South Africa for populations aged between 15 and 49 years. In South Africa alone ∼320,000 individuals are reported to die annually on account of an AIDSrelated illness. [3] [4] [5] [6] [7] Even in a cosmopolitan city like New York, it is estimated that there are 100,000 HIV-positive individuals and of these ∼20% have not been diagnosed. 8−10 In Africa the percentage of undiagnosed HIV-positive individuals is higher than in North America. 11, 12 As a result of this large undiagnosed population, the CDC recently modified its position and now recommends HIV testing of individuals aged 13 to 64 years as part of an annual medical examination. 13 Early identification of infection is associated with increased initial cost, but intervention based on a diagnostic result allows an appropriate therapeutic response (FIG. 1) , 14 ultimately reducing costs to society. Great Britain's National Health Service recently asked "How much is it worth spending to prevent one new HIV infection or transmission?" The Department's health economists estimated that the monetary value of preventing a new single transmission of HIV is between pound 0.5 and pound 1 million in individual health benefits and treatment costs. 15 In South Africa, SABMiller, one of the world's largest 14 ) brewers, was reported by the Wall Street Journal to have initiated an employee testing and treatment program that provides counseling and therapy in order to decrease the loss of highly trained workers. 16 The economic consequences of NOT testing for HIV infection are staggering. Early diagnosis through testing ultimately saves money by breaking the chain of transmission and has been responsible for the dramatic decrease in the spread of the disease in the United States. Closing the "window" from the time of infection to seroconversion has the potential to further reduce the spread of HIV disease and increase therapeutic effectiveness. 17, 18 Because people do not die from an HIV infection, but rather from other opportunistic infections, such as tuberculosis, intestinal tract infections, and progressive multifocal leukoencephalopathy, 19 we envision developing modules for multiple HIV-associated pathogens. Existing screening tests for HIV require the subject to return for results of a confirmatory test, which has a low compliance rate and is associated with a number of social dynamic issues. 9 A point-of-care (POC) confirmatory test would alleviate this problem.
Device Concept
Our focus from the outset was to address the lack of diagnostic testing for infectious diseases. We wanted to build a simple to use, rapid, POC device for diagnosis of HIV and other bacterial-viral infections because of the pressing need. HIV is clearly an important disease, but it is also a good model for a proofof-concept of a confirmatory test by employing a multiplex analysis paradigm: parallel processing of multiple analytes for antigen, antibody, and/or nucleic acid. However, because of opportunistic infections associated with HIV, it is important to simultaneously detect other bacterial and viral pathogens. Other infectious agents have become apparent in patients receiving antiretroviral drug treatment, including many bacteria, 20 fungi, and protozoan and viral pathogens that can effectively be treated with drugs if diagnosed.
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Challenge
We are using a modular design strategy to build a device that ultimately will provide testing for multiple pathogens using saliva as a noninvasive source of test material, detecting pathogens by antigen, antibody, and/or nucleic acid, by use of multiplex analysis. Any one of these tests is available today although not packaged together and the impact of simultaneous, multiple analyte testing is to increase the overall test accuracy and its diagnostic usefulness. 17 A schematic was constructed of the tests the device needed to include. All the techniques were available as bench-top procedures; including nucleic acid isolation and amplification (reverse transcriptase-polymerase chain reaction [RT-PCR] and/or PCR) and identification of antigen or antibody by an enzyme-linked immunosorbent assay (ELISA) or Western blot approach. Modifications of these techniques to microscale presented engineering challenges that included controlling the surface area of channels and chambers relative to the volume of sample, dealing with the movement of small volumes of liquid, small amounts of target, and the required sensitivity of the reporter. Also, to be of maximum use, results are best obtained in less than 1 h.
Sample Collection
The standardized collection of oral fluid was addressed in a study that compared eight different collectors for their ability to pick up and release bacteria, protein, and virus. 21 The OraSure UPlink TM was chosen because of its overall performance characteristics and in addition it was already an FDA-approved device. The collector is a pencil-like device with a compressed cellulose-like sponge that expands and can collect ∼300 L of fluid when inserted into the mouth between the gum and the cheek for 1 min (Fig. 2A) . The schematic (FIG. 2B) shows the compressed sponge releasing oral fluid into a channel as it is inserted into the assay cassette.
Microchip Components
Several components are required for a disposable microfluidic chip construction and operation. These include the chip substrate, mechanism for fluid movement, mixing, measurement of volume, PCR chamber configuration, passivation of surfaces, valves, connectors, reporter, and reporter detection. FIGURE 3 shows a number of different valves that were developed to evaluate which was the most efficient and effective one. The phase change (FIG. 3A) uses a thermoelectric unit to maintain a channel at −20
• C so that the flow stops on freezing when liquid enters the cooled area, and subsequent warming allows the flow to continue; 22 the hydrogel valve 23 (FIG. 3B) uses a hydroscopic matrix prepared from acrylamide that swells when in contact with an aqueous solution at ambient temperatures and shrinks again when heated; a passive valve (FIG. 3C) that takes advantage of surface tension to stop flow under low pressures; a check valve (FIG. 3D) that prevents back flow of reagent; and a deformable valve (FIG. 3E) that is fabricated with a thin-film deformable membrane over a channel combined with an external actuator pin that blocks flow.
PCR Chambers
PCR has been performed by shuttling a bolus of fluid containing nucleic acid with appropriate reagents between zones of different temperatures using a syringe pump under computer control. 24 We also developed a buoyancy or thermosiphon-based PCR (FIG. 4) , a unique design that automatically generates a circular flow through changes in thermally induced density changes within the loop that includes all the reagents necessary for PCR. 22, 25 Amplification of target occurs as reagents cycle through the temperature zones. However, the operating plane of the loop must be set at an angle of 90
• to gravity, which is currently not compatible with the cassette's horizontal format. The current chip will use a static PCR chamber consisting of a 10-L well fitted with a thermoelectric heater and thermister.
Microfluidic Chips
An example of a microfluidic chip for PCR-based detection is shown in FIGURE 5. This hydraulically driven chip is capable of receiving a fluid sample, metering its volume, lysing any pathogen present, isolating nucleic acid, performing PCR, incubating with reporter conjugate, lateral flow immunochromatography, and detecting the amplified product. FIGURE 5B shows the chip incorporated into a cassette. Another chip module has been constructed to perform consecutive flow upconverting phosphor technology (UPT) simultaneous detection of TB, HCV, and HIV antibodies.
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FIGURE 4. Photograph of the thermosiphon PCR chamber that operates in a vertical orientation by the density changes induced by heating and cooling of the PCR reaction mix. 
Common Reporter
UPT was selected as the detection reporter because of its high signal-tonoise ratio for biological samples in a miniaturized format that is compatible with lateral flow. 27 UPT particles are ceramic spheres containing rare earth molecules that can absorb multiple photons of infrared light (980 nm) and emit visible light in the green part of the spectrum (550 nm).
27 Different combinations of rare earths can be used to produce different visible colors. This process converts lower energy to higher energy, a process that does not normally exist in nature and consequently has no natural background (FIG.  6) . The particles are silica coated to both passivate the ceramic surface and allow covalent conjugation of biomolecules, which "functionalizes" the UPT particles as a reporter. The UPT particles have been used in a number of different diagnostic assays.
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Lateral Flow Detection
A nitrocellulose-based lateral flow strip is a simple and inexpensive technique for the chromatographic separation of target bound to reporter from excess reporter. 31 Typically, a lateral flow strip (FIG. 7) has at least two capture lines, a test and a control line. The test line binds the target reporter complex and the control line verifies that flow has reached the end of the strip by binding free reporter. The waste pad functions as a sink that ensures that reagents do not flow backward toward the test line area. The capture lines take advantage of high-affinity binding pairs, such as biotin to avidin or between an antigen and its antibody to form a sandwich. The schematic (FIG. 7B) illustrates a simplified view of how the strip functions for recognition of a PCR amplicon (the DNA target) that was labeled with biotin and digoxigenin. The target reporter complex (biotinylated DNA target bound to avidin-coated UPT reporter particles) and free reporter (avidin-coated UPT reporter particles) are trapped at the test and control lines, respectively, as they flow past their binding partner. The capture lines are then interrogated with IR light (980 nm) and the UPT-emitted light (550 nm) is recorded.
METHODS AND RESULTS
Comparison of Nucleic Acid Fluorescence
Staining with UPT Detection PCR was performed on S. pyogenes DNA isolated from ∼10 7 cells in a twofold dilution series (FIG. 8) . Each dilution was then amplified using biotinylated and digoxigenin-labeled primers. Panel A shows the PCR reaction product (10 L) after 25 cycles of PCR, electrophoresed on a 2% agarose gel. Panel B shows the relative fluorescence ratios (test line/control line) obtained with UPT detection using 1 L of PCR product as described in the methods section. Note the increased sensitivity with UPT detection.
Chip Docking
Mating the chip to a buffer or reagent reservoir requires a quick connection to occur as the disposable chip is inserted into the reader. Fabrication from polyethylene or aluminum of a simple conical male fitting allows for a leak-free seal to 29 psi when mated with a polycarbonate seat using minimal joining pressure, which is well below the chip's operating pressures.
Multiplex Detection
S. pyogenes and B. cereus
Multiplexing was carried out with an optimized PCR protocol using Eppendorf Taq DNA polymerase and primers designed for each organism (FIG. 9) . These results confirm that multiple bacteria can be simultaneously amplified. 
Multiplex Detection of S. pyogenes or B. cereus and HIV
To demonstrate the ability to simultaneously detect virus and bacteria in an oral fluid sample, we isolated these together in saliva or plasma and performed simultaneous PCR and RT-PCR. Virus and bacteria were added to whole saliva and nucleic acid isolated using a Qiagen RNAeazy RNA extraction kit. The capability to simultaneously detect amplicon products from both HIV and S. pyogenes in saliva is documented in FIGURE 10, which shows representative lanes from an ethidium bromide-stained agarose gel electrophoresis separation together with the results of digital quantitation. FIGURE 11 shows a similar experiment for the simultaneous detection of B. cereus and HIV comparing the ability to amplify in the presence of buffer, saliva, or serum.
SUMMARY
A modular design strategy has been used to build a diagnostic device for infectious disease detection by performing multiple tests for targets in parallel and employing a standardized collection device, the UPlink TM collector, and a common sensitive reporter (UPT). We have carried out simultaneous determinations of S. pyogenes and B. cereus, HIV and B. cereus, and HIV and S. pyogenes in oral fluid. The use of UPT for a reporter provides a 3-order-ofmagnitude enhancement of sensitivity over conventional ethidium bromidestained agarose gels.
